• C2Sense

  Participated · Seed · Sep 2017

  C2Sense is building the world’s largest digital olfactory platform to transform smell into real-time data for industrial Internet of Things applications. Its patented gas-sensing technology, developed by MIT founders including Tim Swager and CEO Jan Schnorr, can be designed to selectively detect a wide range of compounds. The sensors pair with a data platform and service so customers can access information and recommendations remotely; the technology is described as small, portable, and affordable for broad deployment. Cited use cases include estimating remaining shelf life to reduce food waste and monitoring toxic gases to protect workers. Founded in 2014 and based in Cambridge, Mass., C2Sense has drawn early traction across multiple applications. The company announced a $3.2 million seed round that management says will help accelerate connecting the real world of smell with digital data.

• Carmell Therapeutics

  Participated · Series A · Apr 2011

  Carmell Therapeutics, a spinout from Carnegie Mellon University in Pittsburgh, develops regenerative-medicine technologies based on patented Plasma-based Bioactive Materials (PBMs) manufactured from human blood plasma. Its PBMs concentrate natural regenerative factors to promote healing, reduce infections and complications, and can be formed into putties, pastes, scaffolds, plugs, screws and sheets. The company’s lead product candidate is Bone Healing Accelerant. Carmell closed a $4M Series B to advance that candidate into phase III clinical development. The company positions its technology to save healthcare costs by improving healing across multiple clinical settings. Carmell Therapeutics develops biologically active plastics made from blood plasma intended to promote healing of bone and connective tissue. Its first product is an arthroscopically placed surgical scaffold placed between bone and tendon to treat rotator cuff and tendon injuries; the scaffold deteriorates over four to six weeks while delivering the body’s growth and regenerative factors. The company is also developing a bone putty as a second product. Carmell plans to use the recent Series A proceeds to set up a manufacturing facility and collect data for a pilot study and hopes a successful pilot will support a larger Series B to fund a clinical trial and pursue federal regulatory clearance. The company disclosed an equity first close of $3 million in an SEC filing and said it will accept additional investments to round out the round; nine investors participated. Carmell was founded in 2007 to commercialize technology developed by Carnegie Mellon University and Allegheny General Hospital and is based in Pittsburgh; CEO Alan West previously served as a Boston Scientific vice president of R&D.

No current team members are available.